Final analysis of a phase III RCT in previously treated inoperable/metastatic HR-positive, HER2-negative breast cancer: datopotamab deruxtecan did not improve overall survival versus chemotherapy (HR 1.01, 95% CI 0.83 to 1.22); later ADC use was 12.3% vs 24.0%.
RCT
Pistilli et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study